Deane Donnigan, originally a clinical pharmacist, will be based in the US. She joins the firm from Framlington where she worked on the healthcare unit trust led by Anthony Milford before becoming lead manager on both the Framlington Healthcare and Biotechnology funds.
David Pinniger will be based in the UK and joins Polar from SV Life Sciences where he was manager of the International Biotechnology Trust. Prior to this he worked as biotechnology analyst at venture capital firm Abingworth.
The healthcare team is headed up by Gareth Powell and Daniel Mahony and currently manages two vehicles, the Polar Capital Healthcare Opportunities Fund and the Polar Capital Global Healthcare Growth and Income Trust.
The majority of the fund’s capital is currently invested in North America, 79.3%, and in terms of sector pharmaceuticals accounts the largest proportion at 32.56%. The fund’s performance over the past year is shown in the graph below.
true
In May the firm revealed that it may launch a third investment trust focusing on financials.
